Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Production and Characterization of Single Chain Nimotuzumab: An in Vitro Study Publisher



Pourafshar M1 ; Safdari Y1, 2 ; Khajeniazi S2 ; Yazdani Y3 ; Banisadr A1 ; Veisi K4
Authors

Source: International Journal of Peptide Research and Therapeutics Published:2018


Abstract

Recombinant expression and EGFR-binding activity assay of single chain nimotuzumab (nimotuzumab scFv) is reported in this study. The scFv was produced in VH-linker-VL format in Origami™ 2(DE3)pLysS bacterial cells and purified using Ni-TNA resin column. 3-D structure prediction using I-TASSER (Iterative Threading Assembly Refinement) server and analyzing the predicted models using YASARA (Yet Another Scientific Artificial Reality Application) viewer revealed that VH and VL domains assemble into a correctly-folded single chain antibody that is able to bind EGFR. The scFv was evaluated in ELISA and western blot tests and proven to be able to bind EGFR-overexpressing cancer cells (A-431 cells in an efficient manner but unable to recognize cancer cells expressing low levels of EGFR (MCF-7 breast cancer cells). © 2017, Springer Science+Business Media New York.
Related Docs
View other Related Docs
1. Production of a Germline-Humanized Cetuximab Scfv and Evaluation of Its Activity in Recognizing Egfr- Overexpressing Cancer Cells, Human Vaccines and Immunotherapeutics (2018)
2. Development of a Met-Targeted Single-Chain Antibody Fragment As an Anti-Oncogene Targeted Therapy for Breast Cancer, Investigational New Drugs (2023)
3. Bioinformatics Prediction and Experimental Validation of Vh Antibody Fragment Interacting With Neisseria Meningitidis Factor H Binding Protein, Iranian Journal of Basic Medical Sciences (2020)
Experts (# of related papers)
View all Related Experts
Forough Golsaz Shirazi (4)
Mohammad Mehdi Amiri (4)
Other Related Docs
4. A Novel Anti-Her2 Bispecific Antibody With Potent Tumor Inhibitory Effects in Vitro and in Vivo, Frontiers in Immunology (2021)
5. A Novel Fc-Engineered Anti-Her2 Bispecific Antibody With Enhanced Antitumor Activity, Journal of Immunotherapy (2023)
6. New Insights Into Affinity Proteins for Her2-Targeted Therapy: Beyond Trastuzumab, Biochimica et Biophysica Acta - Reviews on Cancer (2020)
7. Antibody Based Epcam Targeted Therapy of Cancer, Review and Update, Current Cancer Drug Targets (2018)
8. Bioinformatics Evaluation of Novel Ribosome Display-Selected Single Chain Variable Fragment (Scfv) Structure With Factor H Binding Protein Through Docking, Journal of Theoretical and Computational Chemistry (2017)
9. Nanobodies As Novel Agents for Targeting Angiogenesis in Solid Cancers, Frontiers in Immunology (2017)
10. Production of Human Single-Chain Fragment Antibody (Scfv) Against Human Epidermal Growth Factor Receptor-2 (Her-2) by Phage Display Technology, In Vitro Cellular and Developmental Biology - Animal (2018)
11. In Silico Mutagenesis in Recombinant Human Keratinocyte Growth Factor: Improvement of Stability and Activity in Addition to Decrement Immunogenicity, Journal of Molecular Graphics and Modelling (2020)
12. Bevacizumab Antibody Affinity Maturation to Improve Ovarian Cancer Immunotherapy: In Silico Approach, International Journal of Peptide Research and Therapeutics (2019)
13. Structure-Based Pharmacophore Design and Virtual Screening for Novel Potential Inhibitors of Epidermal Growth Factor Receptor As an Approach to Breast Cancer Chemotherapy, Molecular Diversity (2018)
14. Expression and Functional Characterization of an Anti-Cd22 Scfv Targeting B-Cell Malignancies, Research in Pharmaceutical Sciences (2025)
15. Inhibitory Effect of Polyclonal Antibodies Against Her3 Extracellular Subdomains on Breast Cancer Cell Lines, Asian Pacific Journal of Cancer Prevention (2020)
16. Development of a Recombinant Anti-Vegfr2-Epcam Bispecific Antibody to Improve Antiangiogenic Efficiency, Experimental Cell Research (2021)
17. Generation of the Fluorescent Hpv16 E7 Protein for Detection of Delivery in Vitro, Protein and Peptide Letters (2018)
18. Hersintuzumab: A Novel Humanized Anti-Her2 Monoclonal Antibody Induces Potent Tumor Growth Inhibition, Investigational New Drugs (2018)
19. Use of Single-Chain Antibody Derivatives for Targeted Drug Delivery, Molecular Medicine (2016)
20. Monoclonal Antibody-Based Therapeutics, Targeting the Epidermal Growth Factor Receptor Family: From Herceptin to Pan Her, Journal of Pharmacy and Pharmacology (2018)